Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005 · Clinical Cancer Research · 1,869 citations
https://doi.org/10.1158/1078-0432.ccr-04-2421
J
James Stec
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
6.1K
Citations
26
h-index
29
i10-index
James Stec is an academic researcher from AbbVie (United States). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Gene expression and cancer classification. The author has an h-index of 26, co-authored 48 publications.
Papers by this author
worksTargeted Therapy in Breast Cancer
2004 · Molecular & Cellular Proteomics · 303 citations
https://doi.org/10.1074/mcp.r400001-mcp200
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
2003 · PubMed · 234 citations
HER-2/neu Testing in Breast Cancer
2003 · Pathology Patterns Reviews · 62 citations
https://doi.org/10.1309/949fpq1aq3p0rlc0
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
2024 · Gynecologic Oncology · 27 citations
https://doi.org/10.1016/j.ygyno.2024.01.045
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
2020 · Investigational New Drugs · 26 citations
https://doi.org/10.1007/s10637-020-00995-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat